Prelude Therapeutics Announces Launch of Proposed Public Offering
04 janv. 2021 16h16 HE
|
Prelude Therapeutics, Inc.
WILMINGTON, Del., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (“Prelude” or “the Company”) (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced that...
Prelude Therapeutics Announces Third Quarter 2020 Financial Results
10 nov. 2020 07h30 HE
|
Prelude Therapeutics, Inc.
- Completed Initial Public Offering of Common Stock, Raising Gross Proceeds of ~$181.9M - - Partial Response Confirmed in Glioblastoma Multiforme Patient in Phase 1 Trial of PRT811 - - Durable...
Prelude Therapeutics Announces Dosing of First Patient in Phase 1 Trial of MCL1 Inhibitor PRT1419 for the Treatment of Relapsed/Refractory Hematologic Malignancies
30 sept. 2020 07h00 HE
|
Prelude Therapeutics, Inc.
WILMINGTON, Del., Sept. 30, 2020 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced that the first patient has been...
Prelude Therapeutics Announces Closing of Initial Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
29 sept. 2020 16h05 HE
|
Prelude Therapeutics, Inc.
WILMINGTON, Del., Sept. 29, 2020 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced the closing of its initial public...
Prelude Therapeutics Announces Pricing of Initial Public Offering
24 sept. 2020 20h50 HE
|
Prelude Therapeutics, Inc.
WILMINGTON, Del., Sept. 24, 2020 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced the pricing of its initial public...